BUSULFAN AND CYCLOPHOSPHAMIDE VERSUS CYCLOPHOSPHAMIDE AND TOTAL-BODY IRRADIATION FOR MARROW TRANSPLANTATION IN CHRONIC MYELOGENOUS LEUKEMIA - A REVIEW

被引：15

作者：

SANTOS, GW

机构：

[1] The Johns Hopkins Bone Marrow Transplantation Program, The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, MD

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 11卷

关键词：

BUSULFAN; TBI; CYCLOPHOSPHAMIDE; MARROW TRANSPLANTATION;

D O I：

10.3109/10428199309047886

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Allogeneic bone marrow transplantation (BMT) for chronic myelogenous leukemia (CML) offers the only significant chance of cure for this disease. About 50% of patients transplanted in the 1980s appear to be cured and with subsequent advances, it is suggested that more patients transplanted in the 1990s will be cured. Cyclophosphamide (Cy) (120 mg/kg) followed by fractionated total body irradiation (TBI) (Cy2/TBI) has been usually employed in preparation for BMT. Alternative regimens of Busulfan (Bu) (16 mg/kg) and Cy (120 mg/kg) (Bu/Cy2) or Bu (16 mg/kg) and Cy (200 mg/kg) (Bu/Cy4) have more recently been employed. At least three studies of Bu/Cy2 or Bu/Cy4 have given encouraging results. Two ongoing randomized studies of Bu/Cy2 versus Cy2/TBI have shown no difference in the event free survival (EFS). In addition, two ongoing randomized studies of Bu/Cy4 versus Cy (200 mg/kg) plus TBI (Cy4/TBI) show no significant differences in EFS. It appears that Bu/Cy regimens are as effective as Cy/TBI regimens. The choice of one regimen over the other depends on matters other than therapeutic efficacy.

引用

页码：201 / 204

页数：4

共 26 条

[1]

Goldman J.M., Bone marrow transplantation for chronic myelogenous leukemia, Curr. Opin. Oncol., 4, pp. 259-263, (1992)

[2]

Champlin R., Bone marrow transplantation for chronic myelogenous leukemia, Curr. Opin. Oncol., 2, pp. 258-262, (1990)

[3]

Messner H.A., Bone marrow transplantation in hematopoietic malignancies, Curr. Opin. Oncol., 3, pp. 245-253, (1991)

[4]

Wagner J.E., Zahurak M., Piantadosi S., Geller R.B., Vogelsang G.B., Wingard J.R., Saral R., Griffin C., Shah N., Zehnbauer B.A., Ambinder R., Burns W., Jones R., May W.S., Rowley S., Yeager A., Santos G.W., Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits, J. Clin. Oncol., 10, pp. 779-789, (1992)

[5]

Thomas E.D., Clift R.A., Fefer A., Appelbaum F.R., Beatty P., Bensinger W.I., Buckner C.D., Cheever M.A., Deeg H.J., Doney K., Flournoy N., Greenberg P., Hansen J.A., Martin P., McGuffin R., Ramberg R., Sanders J.E., Singer J., Stewart P., Storb R., Sullivan K., Weiden P.L., Witherspoon R., Marrow transplantation for the treatment of chronic myelogenous leukemia, Ann. Int. Med., 104, pp. 155-163, (1986)

[6]

Champlin R.E., Goldman J.M., Gale R.P., Bone marrow transplantation in chronic myelogenous leukemia, Sem. Hematol., 25, pp. 74-80, (1988)

[7]

Goldman J.M., Gale R.P., Horowitz M.M., Biggs J.C., Champlin R.E., Gluckman E., Hoffmann R.G., Jacobsen S.J., Marmont A.M., McGlave P.B., Messner H.A., Rimm A.A., Rozman C., Speck B., Tura S., Weiner R.S., Bortin M.M., Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion, Ann. Int. Med., 108, pp. 806-814, (1988)

[8]

Thomas E.D., Clift R.A., Indications for marrow transplantation in chronic myelogenous leukemia, Blood, 73, pp. 861-864, (1989)

[9]

Copelan E.A., Grever M.R., Kapoor N., Tutschka P.J., Marrow transplantation following busulfan and cyclophosphamide for chronic myelogenous leukemia in accelerated or blastic phase, Br. J. Haematol., 71, pp. 1978-1984, (1989)

[10]

Santos G.W., Tutschka P.J., Brookmeyer R., Saral R., Beschorner W.E., Bias W.B., Braine H.G., Burns W.H., Elfenbein G.J., Kaizer H., Mellits D., Sensenbrenner L.L., Stuart R.K., Yeager A.M., Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide, N. Eng. J. Med., 309, pp. 1347-1353, (1983)

← 1 2 3 →